Neil Dahiya

Exploring Enhanced Venezuela-India Pharmaceutical Collaboration with Emphasis on Quality Control and Trade Barriers

In a major effort to boost pharmaceutical trade ties between India and Venezuela, a recent webinar delved into the hurdles and possibilities for increasing Indian pharmaceutical exports to Venezuela. This event, attended by crucial industry stakeholders, was co-hosted by the

Exploring Enhanced Venezuela-India Pharmaceutical Collaboration with Emphasis on Quality Control and Trade Barriers Read More »

Lipella Pharma finishes dosing first cohort in phase 2a study of LP-310 for oral lichen planus treatment

Lipella Pharmaceuticals Inc., a biopharmaceutical company dedicated to pioneering treatments for serious ailments with significant unmet clinical needs, announced the conclusion of dosing for the initial cohort in its phase 2a multi-site clinical study of LP-310. LP-310 is a liposomal-tacrolimus

Lipella Pharma finishes dosing first cohort in phase 2a study of LP-310 for oral lichen planus treatment Read More »

CapeStart Launches MadeAi: An AI-Driven Platform Revolutionizing Life Science Literature Review

During the ISPOR Europe 2024 Conference, CapeStart, Inc. launched MadeAi, a platform powered by generative AI, designed to significantly optimize the consolidation of clinical data. Its first application, MadeAi-LR, redefines the efficiency of literature reviews, assisting systematic literature reviews (SLRs),

CapeStart Launches MadeAi: An AI-Driven Platform Revolutionizing Life Science Literature Review Read More »

China’s NMPA Greenlights Merck’s Welireg for Adult Von Hippel-Lindau-Related Tumors

Merck, recognized globally as MSD outside the Americas, has announced that China’s National Medical Products Administration (NMPA) has granted approval for Welireg (belzutifan) to be used in adult patients with von Hippel-Lindau (VHL) disease who need treatment for associated tumors

China’s NMPA Greenlights Merck’s Welireg for Adult Von Hippel-Lindau-Related Tumors Read More »

Bioretec Enters US Market with New Sales Partnership for RemeOs Trauma Screw Distribution

Bioretec Ltd, a trailblazing organization committed to innovating biodegradable orthopedic solutions, is propelling forward with the next stage of bringing its cutting-edge RemeOs Trauma Products to the US marketplace. Building on an earlier logistics agreement with GlobalMed Logistix, Bioretec is

Bioretec Enters US Market with New Sales Partnership for RemeOs Trauma Screw Distribution Read More »

Leads Biolabs Secures US FDA Orphan Drug Status for LBL-024 Antibody Targeting Neuroendocrine Cancer

Nanjing-based Leads Biolabs Co., Ltd., a clinical-stage biotechnology firm established by a team of experienced antibody drug developers trained in the United States, has announced a major advancement in the development of its proprietary bispecific antibody, LBL-024. The United States

Leads Biolabs Secures US FDA Orphan Drug Status for LBL-024 Antibody Targeting Neuroendocrine Cancer Read More »